Rep. Tracey Mann

Maddy summaryThis resolution formally recognizes the 100th anniversary of the Golf Course Superintendents Association of America, honoring its century-long contribution to the golf industry. The bill does not change any laws or allocate funds; instead, it serves as a symbolic commendation for the organization's work in advancing greenkeeping standards, promoting environmental stewardship, and supporting education and workforce development. By acknowledging the association's role in managing golf courses and its impact on the economy and communities, the measure highlights the professional achievements of its members without imposing new regulatory requirements.

Maddy summaryThis bill reauthorizes and expands the Accelerating Access to Critical Therapies for ALS Act through 2031, extending funding for research into treatments for amyotrophic lateral sclerosis. It requires drug manufacturers to share interim clinical trial data with the FDA to better assess the progress of investigational drugs and clarifies that phase 3 clinical trial definitions include combined phase 2/3 trials and planned trials not yet enrolling participants. The legislation also mandates the FDA to publish an updated five-year action plan for ALS and other rare neurodegenerative diseases, including resource needs and coordination strategies with broader disease communities. Additionally, the bill requires the Government Accountability Office to submit a report on the program's implementation four years after enactment.

Maddy summaryThe Preventing Forced Abortions Act of 2026 prohibits federal courts from enforcing any part of a surrogacy agreement that forces a surrogate mother to have an abortion. Instead, the law mandates that courts must uphold the financial compensation promised to the surrogate, even if the contract includes penalties or reduced payments for refusing an abortion. This legislation grants federal district courts specific authority to hear civil cases involving surrogacy contracts and defines key terms such as "abortion" and "surrogate mother" to clarify the scope of the protections.

Maddy summaryThis bill requires pharmacy benefits managers (PBMs) administering prescription drug benefits for federal employee health plans to reimburse pharmacies at specific rates, including the national average drug cost plus a small percentage or $50, whichever is lower. It prohibits PBMs from favoring their own pharmacies, restricting patient choice, or reducing pharmacy payments after claims are processed. The bill establishes $10,000 civil penalties for violations, with debarment from federal health plans after 10 penalties in 10 years. This directly affects PBMs, in-network pharmacies, and federal health benefit plans covering millions of federal employees and their families. The law aims to ensure fair reimbursement practices and maintain pharmacy choice under the Federal Employees Health Benefits Program.

Maddy summaryThis bill, known as the STOP Nitazenes Act, directs the federal government to permanently classify nitazenes and related synthetic opioids as Schedule I controlled substances, placing them in the same legal category as heroin and fentanyl. The legislation specifically targets a broad range of chemical compounds, including etonitazene and other variants, by defining them as 2-benzylbenzimidazole opioids and requiring the Attorney General to publish a list of qualifying substances. Under the bill, any nitazene substance temporarily scheduled under emergency provisions would be made permanently scheduled upon enactment, ensuring long-term federal control. The law also mandates that the Attorney General issue implementing rules within one year, allowing for immediate interim enforcement while providing opportunities for public comment before final regulations are established.

Maddy summaryHR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.

Maddy summaryThe Essential Caregivers Act of 2026 requires nursing homes, long-term care hospitals, rehabilitation facilities, and intermediate care facilities to allow two chosen family members or friends to visit residents during times when regular visitation is suspended. These essential caregivers must agree to follow the facility's existing safety and infection control rules, which are no more restrictive than those applied to staff. While facilities can limit access for the first seven days of a suspension or deny entry if a caregiver shows symptoms of a serious infectious disease, they cannot block visits for end-of-life care. Additionally, the bill mandates that complaints about denied access to essential caregivers be investigated and resolved within three days.

Maddy summaryHR 7651, the Chloe Cole Act of 2026, prohibits healthcare providers from performing certain medical interventions on minors under 18 aimed at altering physical development to align with gender identity. These "covered interventions" include puberty blockers, hormone treatments, and specific surgeries, but exclude medically necessary care for conditions like disorders of sexual development or traumatic injuries. The bill creates a federal civil lawsuit right for affected minors or their parents against providers who perform such interventions, allowing claims for damages including emotional distress and punitive awards, with strict liability for providers after the law's enactment. It explicitly allows exceptions for legitimate medical treatments and requires providers to prove such exceptions apply if challenged.

Maddy summaryThis bill requires Medicare Advantage plans to implement electronic pre-approval systems for medical services by 2028 and meet transparency reporting standards starting in 2027. Plans must publicly report data on approval/denial rates, appeal outcomes, response times, and technology use for pre-approval requests, including details on how denials relate to clinical criteria. It establishes a 24-hour response timeframe for certain requests and mandates annual reviews of pre-approval requirements based on data and input from seniors and providers. The law directly affects Medicare Advantage plans, seniors enrolled in these plans, and healthcare providers who submit pre-approval requests. These changes aim to make the pre-approval process faster, more transparent, and more accountable for seniors seeking covered medical services.

Protecting Privacy in Purchases Act This bill prohibits payment card networks from using merchant codes that distinguish firearms retailers from general-merchandise retailers or sporting-goods retailers. The Department of Justice must enforce this bill and report annually on the resulting investigations and cases.